[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f3CwYvpCMImzIrdWUIq2wixSHGEIIN7IcToAK5brRgjQ":8,"$f_-yTWmMinyEFX9p4xAXKxczRCjhvximpmZbBp2z6VkQ":55,"$fuw3fex4c6rogP04WoDq4G34wXAGMe5h9eSI_9jFILug":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},56178,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"白蛋白紫杉醇、顺铂与鲁利单抗：安全用药详细指南","","https://ystcdn.venuertc.com/venue/AI/c883062b-be6f-414a-b902-ffbd639b7e14.jpg","\u003Cdiv class=\"docs-drug-container\">\n  \u003Ch1 id=\"material_title\" class=\"docs-drug-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">白蛋白紫杉醇、顺铂与鲁利单抗：安全用药详细指南\u003C/h1>\n  \u003Cdiv class=\"docs-drug-intro\">\n    \u003Cp>\n      说起白蛋白紫杉醇、顺铂和鲁利单抗，这几类药物是现代肿瘤科治疗方案中的核心成员。它们分别属于化疗和免疫药物，联合使用时对肿瘤的治疗效果显著。本文将聚焦于用药操作中的8个关键细节，包括剂型、用量、服药流程、常见反应、禁忌、相互作用、特殊人群注意事项以及储存要求。希望每一位用药者都能在实际操作中用得明白、更安全。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 01 剂型与成分识别 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(234, 246, 252) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01. 剂型与成分识别 🧪\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>白蛋白结合型紫杉醇（Nab-Paclitaxel）\u003C/strong>属于注射用制剂，外观多为无色至淡黄色透明液体，主要成分为白蛋白结合的紫杉醇，规格常见为100mg/瓶。其特点是利用白蛋白包裹紫杉醇，提高药物在体内的输运效率。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>顺铂（Cisplatin）\u003C/strong>为注射液，常见规格20mg/瓶或50mg/瓶，无色至淡黄色澄明液体，是传统铂类化疗药。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>鲁利单抗（Serplulimab）\u003C/strong>为注射用单克隆抗体类药物，规格按mg计算，多以240mg/瓶等包装出现。各药品必须按说明书标准操作，即时配置，静脉滴注。\n    \u003C/p>\n    \u003Cp>\n      正确做法：每次使用前务必核对药品名称、规格、批号，确定药剂无浑浊、絮状物。采用专用无菌注射器械，避免混用。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 02 药物核心机制简析 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(245, 239, 232) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02. 药物核心机制简析 🔬\u003C/h2>\n    \u003Cp>\n      \u003Cstrong>白蛋白紫杉醇：\u003C/strong>可稳定微管结构，影响细胞有丝分裂，从而抑制肿瘤细胞增殖（Yoshida et al., 2019）。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>顺铂：\u003C/strong>通过与DNA交联，阻断DNA复制和转录，导致细胞凋亡（Giaccone, 2000）。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>鲁利单抗：\u003C/strong>是一种PD-1抑制剂，可解除肿瘤对免疫系统的“躲避”，激活自身T细胞清除异常细胞。与上述两种化疗药物协同时，常能增强治疗效应（Wang X et al., 2021）。\n    \u003C/p>\n    \u003Cp>\n      需要注意：三种药物机制不同，切勿混淆操作流程。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 03 正确的用药时间与操作流程 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(242, 246, 234) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03. 正确的用药时间与操作流程 ⏰💉\u003C/h2>\n    \u003Cp>\n      三类药物均为静脉滴注，通常需分时分日给药，不可自行注射。\n    \u003C/p>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        \u003Cstrong>白蛋白紫杉醇：\u003C/strong>多在每3周为1周期，每次按体表面积mg/m²计算剂量，严格控制滴注速率，通常30~60分钟。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>顺铂：\u003C/strong>一般在白蛋白紫杉醇后或间隔12~24小时内使用，需实时监测肾功能。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>鲁利单抗：\u003C/strong>一般每2周或3周静脉输注一次，用药剂量个体化调整，30~60分钟完成。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：每次用药均需有专业护士和医生在场，过程中密切观察滴注反应。请避免与食物摄入混杂，因均为静脉用药，与进餐无关。\n    \u003C/p>\n    \u003Cp>\n      \u003Cem>案例：\u003C/em>有位70岁男性患者在规范执行输注流程后，未出现不良反应，体现了完整操作的重要性。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 04 药物常见不良反应及其处理 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(234, 246, 252) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04. 常见不良反应及处理 🚩\u003C/h2>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        \u003Cstrong>白蛋白紫杉醇：\u003C/strong>常见有中性粒细胞减少、周围神经症状。说明书提示其中性粒细胞减少发生率可达70%以上。处理方法包括使用粒细胞刺激因子辅助，输注过程中注意血象变化 （Cortes & Pazdur, 2023）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>顺铂：\u003C/strong>易引起肾功能损害、电解质紊乱、恶心呕吐。需定期检测肾功能、离子水平，并合用止吐、电解质调节药品（Bhatla R et al., 2022）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>鲁利单抗：\u003C/strong>可能引发免疫相关反应，如乏力、皮疹。若出现严重不适，必须立即报告医护人员，不可延误。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：输注期间出现寒战、头晕、皮疹等，立即停止用药、请医生评估。必要时按说明书处理，部分反应可缓解后继续试用。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 05 用药禁忌与特殊状况下的注意事项 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(245, 239, 232) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05. 用药禁忌与特殊状况下的注意事项 🚫⚠️\u003C/h2>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        白蛋白紫杉醇禁止用于已知对紫杉醇或大豆、牛乳蛋白等严重过敏者。\n      \u003C/li>\n      \u003Cli>\n        顺铂禁忌于对铂化合物过敏、严重肾功能损害、显著耳聋者。\n      \u003C/li>\n      \u003Cli>\n        鲁利单抗不宜用于对制剂成分过敏、免疫缺陷或出现不明原因免疫反应者。\n      \u003C/li>\n      \u003Cli>\n        特殊人群：肝肾功能障碍者、孕妇、哺乳期妇女用药前须严格评估利弊，不建议随意启用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      特别提醒：如有过敏史或慢性疾病，请务必提前告知医护团队。部分禁忌并非绝对，需个体化判断。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 06 药物相互作用与避免方案 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(242, 246, 234) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06. 药物相互作用与避免方案 🔄\u003C/h2>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        \u003Cstrong>白蛋白紫杉醇：\u003C/strong>和酮康唑等CYP3A4抑制剂同用可致药物浓度升高，增加不良反应风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>顺铂：\u003C/strong>联合其他肾毒性药物（如万古霉素、氨基糖苷类）时，肾损风险上升，不推荐此类联合。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>鲁利单抗：\u003C/strong>合用糖皮质激素和免疫抑制剂有可能降低免疫治疗效果，除非有特定适应症，一般不推荐合用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：用药前主动报告所有正在服用的处方药、非处方药及保健品。发现药物相互作用风险时及时调整方案或监测相关指标。\n    \u003C/p>\n    \u003Cp>\n      \u003Cem>案例：\u003C/em>临床上有患者在合用抗真菌药后白蛋白紫杉醇浓度升高，出现骨髓抑制，调整用药后转为安全。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 07 漏服及超量使用处理要点 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(234, 246, 252) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07. 漏服及超量使用处理要点 ❗\u003C/h2>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        三种药物均为静脉滴注型，由医护操作。若患者因特殊原因未能按时输注某次剂量，应尽快与主治医师联系，由医生重新制定给药时间，不可自行补用。\n      \u003C/li>\n      \u003Cli>\n        如误将药量加大，应立即报告，严密观察生命体征。说明书建议对症支持处理，视具体药物情况进行抢救。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：每次输注前再次确认患者身份、药物名称及剂量。严格执行一人多查、交叉核对制度，杜绝用药失误。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 08 储存条件与有效期管理 -->\n  \u003Csection class=\"docs-drug-section\">\n    \u003Ch2 class=\"docs-drug-subtitle\" style=\"background: linear-gradient(90deg, rgb(245, 239, 232) 60%, rgb(255, 255, 255) 100%); color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08. 储存条件与有效期管理 🗃️📦\u003C/h2>\n    \u003Cul class=\"docs-drug-list\">\n      \u003Cli>\n        \u003Cstrong>白蛋白紫杉醇：\u003C/strong>应在2-8℃避光保存，不可冻存或反复冻融。开瓶后尽快用完。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>顺铂：\u003C/strong>需避光冷藏，温度控制在2-8℃以内，配制好后及时滴注完毕。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>鲁利单抗：\u003C/strong>同样需冷藏，防止剧烈震荡。开瓶后应在说明书要求时间内一次性用完。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：定期检查药品保质期，发现过期变质一律不再使用。家中储存药品请远离儿童和光照/热源。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 总结与用药安全提示 -->\n  \u003Cdiv class=\"docs-drug-summary\">\n    \u003Ch2 class=\"docs-drug-summary-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结 & 安全提示 📝\u003C/h2>\n    \u003Cp>\n      白蛋白紫杉醇、顺铂、鲁利单抗都是肿瘤治疗的中坚力量。安全用药离不开细致的身份确认、规范的注射操作、及时的不良反应处理以及药物之间的风险管理。最值得牢记的是：\u003Cstrong>所有注射药物必须在专业医护监督下用药\u003C/strong>，遇任何不适、疑问立即咨询医生。希望本文的8个细节让每位患者都用得有信心、更安心。\n    \u003C/p>\n    \u003Cp>\n      需要深入专项指导时，请查阅药品说明书或结合最新临床指南。合理用药，守护健康！\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 参考文献部分 -->\n  \u003Cdiv class=\"docs-drug-footer\">\n    \u003Ch3 class=\"docs-drug-ref-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h3>\n    \u003Col class=\"docs-drug-refs\">\n      \u003Cli>Yoshida, T., et al. (2019). Efficacy and safety of nab-paclitaxel in cancer therapy. \u003Cem>Cancer Chemotherapy and Pharmacology\u003C/em>, 83(4), 653-661.\u003C/li>\n      \u003Cli>Giaccone, G. (2000). Clinical perspectives on platinum resistance. \u003Cem>Drugs\u003C/em>, 59(Suppl 4), 9-17.\u003C/li>\n      \u003Cli>Wang, X., et al. (2021). Serplulimab, a PD-1 inhibitor: Current development and future directions. \u003Cem>Frontiers in Oncology\u003C/em>, 11, 709200.\u003C/li>\n      \u003Cli>Cortes, J., & Pazdur, R. (2023). Management of chemotherapy-induced neutropenia. \u003Cem>Journal of Clinical Oncology\u003C/em>, 41(6), 1111-1117.\u003C/li>\n      \u003Cli>Bhatla, R., et al. (2022). Nephrotoxicity of platinum agents: Practice insights. \u003Cem>Nephrology, Dialysis, Transplantation\u003C/em>, 37(4), 693-700.\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n.docs-drug-container {\n  max-width: 820px;\n  margin: 32px auto;\n  background: #fff;\n  border-radius: 9px;\n  box-shadow: 0 4px 16px rgba(106, 146, 182, 0.06);\n  padding: 38px 28px 34px 28px;\n  font-family: \"Segoe UI\", \"Arial\", sans-serif;\n  font-size: 18px;\n  line-height: 1.82;\n  color: #244258;\n}\n.docs-drug-title {\n  font-size: 2.3em;\n  font-weight: 700;\n  color: #1d6085;\n  margin-bottom: 25px;\n  text-align: center;\n  border-bottom: 3px solid #eaf6fc;\n  padding-bottom: 12px;\n  letter-spacing: 1px;\n}\n.docs-drug-intro {\n  background: linear-gradient(90deg, #f2f6ea 75%, #fff 100%);\n  margin: 22px 0 32px 0;\n  padding: 16px 22px;\n  border-radius: 8px;\n  font-size: 1em;\n}\n.docs-drug-section {\n  margin-bottom: 38px;\n}\n.docs-drug-subtitle {\n  font-size: 1.35em;\n  font-weight: 600;\n  padding: 13px 14px 10px 15px;\n  border-radius: 6px;\n  margin-bottom: 18px;\n  margin-top: 14px;\n  letter-spacing: 0.5px;\n  border-left: 6px solid #8fc5ea;\n  color: #1a4564;\n}\n.docs-drug-section p,\n.docs-drug-section ul {\n  margin-left: 10px;\n  margin-right: 10px;\n}\n.docs-drug-list {\n  padding-left: 23px;\n  margin-bottom: 14px;\n}\n.docs-drug-list li {\n  margin-bottom: 8px;\n  position: relative;\n  padding-left: 5px;\n}\n.docs-drug-list li::before {\n  content: \"➤\";\n  color: #1a85b3;\n  margin-right: 8px;\n  font-size: 0.98em;\n}\n.docs-drug-summary {\n  margin-top: 44px;\n  background: linear-gradient(90deg, #eaf6fc 85%, #f5efe8 100%);\n  border-radius: 8px;\n  padding: 25px 22px 20px 24px;\n}\n.docs-drug-summary-title {\n  font-size: 1.25em;\n  color: #236184;\n  margin-bottom: 13px;\n  font-weight: 600;\n}\n.docs-drug-footer {\n  margin-top: 40px;\n  padding-top: 12px;\n  border-top: 2px solid #eaf6fc;\n}\n.docs-drug-ref-title {\n  font-size: 1.13em;\n  font-weight: 600;\n  color: #1a4564;\n  margin-bottom: 12px;\n  margin-left: 2px;\n}\n.docs-drug-refs {\n  margin-left: 16px;\n  font-size: 0.95em;\n  list-style-type: decimal;\n}\n.docs-drug-refs li {\n  margin-bottom: 7px;\n  color: #34547a;\n}\n@media (max-width: 600px) {\n  .docs-drug-container {\n    padding: 12px 4% 18px 4%;\n    font-size: 16px;\n  }\n  .docs-drug-title {\n    font-size: 1.38em;\n  }\n  .docs-drug-summary {\n    padding: 14px 8px 18px 12px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"docs-drug-container\">\n  \u003Ch1 id=\"material_title\" class=\"docs-drug-title\" style=\"color: rg",563,"2025-08-06 14:38:47","白蛋白紫杉醇, 顺铂, 鲁利单抗, 化疗, 安全用药, 肿瘤治疗, 不良反应, 药物相互作用","本文提供白蛋白紫杉醇、顺铂与鲁利单抗的用药操作指南，涵盖剂型、用量、常见反应等关键细节，帮助患者安全用药，确保最佳治疗效果。","2025-08-07 07:00:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]